ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,475.09
0.00%
US Tech 100
19,202.00
-0.39%
Dow Jones
39,169.52
0.00%
Brent Oil
87.035
0.58%
Bitcoin
62,829.17
-0.03%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Cryptocurrencies
  4. COIN
  5. (Cryptocurrency:ROCETH)

  6. (Cryptocurrency:ROCETH) News

ROCETH

(ROCETH)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
07/02/20241:09AMGlobeNewswire Inc.Le KFSH&RC réalise avec succès plus de 5 000 transplantations rénales
07/02/20241:09AMGlobeNewswire Inc.El KFSRC realiza más de 5000 trasplantes renales con éxito
07/02/20241:09AMGlobeNewswire Inc.Il KFSHRC esegue con successo oltre 5.000 trapianti di rene
07/02/20241:00AMGlobeNewswire Inc.Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.EU:BIOSBiosenic
07/02/20241:00AMBusiness WireElliptic Labs Shipping on HONOR Play 60 Plus Smartphone
07/02/20241:00AMGlobeNewswire Inc.Sodexo : poursuite d'une croissance solide au 3e trimestre de l'exercice 2024, en ligne avec les attentesEU:SWSodexo
07/02/20241:00AMGlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
07/02/20241:00AMGlobeNewswire Inc.Sodexo Q3 Fiscal 2024: continued robust growth, in line with expectationsTG:SJ7Sodexo
07/02/20241:00AMGlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialTG:I7GIpsen SA
07/02/20241:00AMGlobeNewswire Inc.Start of Day Message
07/02/20241:00AMGlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
07/02/20241:00AMGlobeNewswire Inc.Medsenic, filiale de BioSenic, a signé une nouvelle série d'accords de licence et de commercialisation avec Phebra PTY Ltd.LSE:0R55Biosenic Sa
07/02/20241:00AMGlobeNewswire Inc.Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.LSE:0R55Biosenic Sa
07/02/20241:00AMGlobeNewswire Inc.Sodexo : poursuite d'une croissance solide au 3e trimestre de l'exercice 2024, en ligne avec les attentesTG:SJ7Sodexo
07/02/20241:00AMGlobeNewswire Inc.Medsenic, filiale de BioSenic, a signé une nouvelle série d'accords de licence et de commercialisation avec Phebra PTY Ltd.EU:BIOSBiosenic
07/02/20241:00AMGlobeNewswire Inc.WISeKey Subsidiary WISeSat.Space to Bring Blockchain to Space for Improved Satellite ServicesNASDAQ:WKEYWISeKey International Holdings AG
07/02/20241:00AMGlobeNewswire Inc.Sodexo Q3 Fiscal 2024: continued robust growth, in line with expectationsEU:SWSodexo
07/02/20241:00AMGlobeNewswire Inc.Ipsen étend sa collaboration et son accord de licence pour le développement de Cabometyx® dans le traitement des tumeurs neuroendocrines avancées sur la base des résultats positifs de l’essai de Phase III CABINETEU:IPNIpsen SA
07/02/20241:00AMGlobeNewswire Inc.Ipsen étend sa collaboration et son accord de licence pour le développement de Cabometyx® dans le traitement des tumeurs neuroendocrines avancées sur la base des résultats positifs de l’essai de Phase III CABINETTG:I7GIpsen SA
07/02/20241:00AMGlobeNewswire Inc.Sodexo Q3 Fiscal 2024: continued robust growth, in line with expectationsEU:SWSodexo
07/02/20241:00AMPR Newswire (Canada)The Bradford Exchange Mint Honors the New Princess of Wales
07/02/20241:00AMPR Newswire (US)The Bradford Exchange Mint Honors the New Princess of Wales
07/02/202412:47AMAlliance NewsAlliance NewsA big Labour majority would be "better" for UK - Starmer
07/02/202412:47AMAlliance NewsAlliance NewsUK food inflation now lower than at any time since 2021, figures show
07/02/202412:46AMAlliance NewsAlliance NewsUK high street retailers facing shareholder pressure over low payLSE:MKSMarks And Spencer Group Plc
07/02/202412:46AMAlliance NewsAlliance NewsUK high street retailers facing shareholder pressure over low payLSE:SBRYSainsbury (j) Plc
07/02/202412:46AMAlliance NewsAlliance NewsUK high street retailers facing shareholder pressure over low payLSE:JD.Jd Sports Fashion Plc
07/02/202412:46AMAlliance NewsAlliance NewsUK high street retailers facing shareholder pressure over low payLSE:SBRYSainsbury (j) Plc
07/02/202412:46AMAlliance NewsAlliance NewsUK PM Sunak to emphasise importance of voting in final stretch plea
07/02/202412:46AMAlliance NewsAlliance NewsIsrael's Netanyahu says end-phase of war on Hamas is close

Your Recent History

USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
EMGE
Emergent Health (PK)
USOTC
GTVH
Golden Triangle Ventures (PK)
USOTC
CNNA
Cann American (CE)
USOTC
TSOI
Therapeutic Solutions (PK)
NASDAQ
NKLA
Nikola
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
TONR
Tonner One World (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NYSE
GME
GameStop
USOTC
VXIT
Virexit Technologies (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
NASDAQ
TSLA
Tesla
USOTC
SMCE
SMC Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved